Ultima Genomics major sequencing award for Singapore's National Precision Medicine (NPM) program Phase III. Nov 02, 2026, 8:00 PM ET * Marks Ultima's first major win to support a national-scale clinical whole genome sequencing initiative * NPM Phase III will leverage Ultima's UG200 Platform and recent advancements that enable large-scale applications, including Solaris 2.0 Chemistry, launched in February 2026. * Ultima will partner with Lucence, a leading Singapore-based clinical lab offering clinical and oncology applications, and QIAGEN, the leader in technologies enabling end-to-end clinical sequencing workflows SINGAPORE and FREMONT, Calif., Nov. 2, 2026 /PRNewswire/ - Ultima Genomics, a company offering a new architecture for enabling ultra-high-throughput next generation sequencing, today announced that its UG200 Sequencing Platform has been selected for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) program, a national initiative focused on advancing the integration of genomics into clinical workflows and healthcare delivery. Precision Health Research, Singapore (PRECISE) is the central coordinating office for the NPM program. The award coincides with recent advancements in Ultima's technology that enable high-quality, large-scale, and low-cost whole genome sequencing, including the launch of Ultima's UG200 Sequencing Platform and Solaris 2.0 chemistry in February 2026. Ultima will support the program through a collaboration with Singapore-based Lucence, a Singapore-based precision medicine leader, and QIAGEN, a global leader in Sample to Insight solutions. NPM Phase III significantly expands the scale and scope of Singapore's precision medicine effort to about 450,000 individuals - nearly one in 10 Singapore residents - with a significant shift toward participants receiving medical treatment and healthcare services. Unlike Phase II, which focused on healthy individuals, Phase III includes patients across a wide spectrum of health conditions from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth. NPM Phase III is intended to generate evidence to support the safe and effective rollout of genetic screening and future integration of genomics into public healthcare. The selection of Ultima technology as part of the Consortium led by Lucence follows an extensive evaluation process. Throughout the process, Ultima and its consortium partners demonstrated a comprehensive approach that addressed quality, clinical readiness, pricing and innovation using Ultima's latest technology, including the UG200 system, Solaris 2.0 chemistry, and bioinformatics analytics. "This award is an important milestone for Ultima Genomics and demonstrates significant advancements to our platform that unlock whole genome sequencing for clinical applications at scale, at low cost, and with high-quality data. NPM Phase III's SG-INSIGHT cohort is an excellent example of how Ultima's drive towards lower costs can support national-scale precision medicine initiatives across geographies worldwide. It also shows how the UG200 can enable our customers and partners to support cost-sensitive initiatives," said Gilad Almogy, Chief Executive Officer of Ultima Genomics. "We are honored to work alongside Lucence and QIAGEN in Singapore and to contribute to a program that is advancing the integration of genomics into healthcare. NPM Phase III's SG-INSIGHT represents an important opportunity to demonstrate how innovation, collaboration, and operational excellence can accelerate precision medicine at a population scale." Under the collaboration, Lucence will provide end-to-end clinical program management and local operational leadership, QIAGEN will support sample preparation and automation workflows, and Ultima will provide sequencing and genomic analysis capabilities designed to enable high-quality, scalable, clinical-grade whole-genome sequencing. Together, the consortium aims to support the successful execution of NPM Phase III and to establish a model for future national genomics initiatives. The award further strengthens Ultima's presence in the Asia-Pacific region and underscores the company's ongoing commitment to advancing population genomics, precision medicine, oncology, rare disease research, and emerging clinical applications across global healthcare systems. SG-INSIGHT is expected to serve as a key reference program as governments, healthcare providers, and research institutions explore broader adoption of precision medicine. Singapore has established itself as a global leader in biomedical innovation and precision medicine. Through collaboration with local healthcare, research, and industry partners, Ultima aims to contribute to the development of a sustainable genomics ecosystem that supports scientific advancement, clinical innovation, and long-term healthcare impact. Ultima continues to advance its sequencing and analysis capabilities to support clinical whole genome sequencing at population scale. These efforts include the recent launch of paired-end sequencing and the development of pangenome-aware WGS analysis, which is expected to be available by year-end 2026. Together, these capabilities will expand the flexibility of Ultima's technology for whole-genome and other large-scale sequencing applications. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change - and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com. About Precision Health Research, Singapore (PRECISE) Precision Health Research, Singapore (PRECISE) leads the National Precision Medicine (NPM) programme, advancing genomics to improve health and grow Singapore's biomedical sector. Phase II sequenced 100,000 Singaporeans, while Phase III, in partnership with Singapore's three healthcare clusters, is evaluating how genomics can be integrated into clinical care responsibly. PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). NPM Phase II is supported by the National Research Foundation, Singapore under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734). Forward-Looking Statements This press release contains forward-looking statements, including statements regarding anticipated benefits from participation in Singapore's National Precision Medicine Program, the expected impact of the NPM Phase III initiative, future sequencing volumes and program expansion opportunities, advancement of precision medicine, growth opportunities in Asia-Pacific and other regions, development of future collaborations, and potential clinical and commercial applications of Ultima's technologies. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect actual results include program timelines, regulatory developments, market conditions, clinical validation outcomes, operational execution, technological performance, and other risks associated with the commercialization and adoption of genomic technologies. Ultima Genomics undertakes no obligation to update forward-looking statements except as required by applicable law. Media Contact Vikki Herrera Oak Street Communications for Ultima Genomics [email protected] 408-206-7009 SOURCE Ultima Genomics NOTE: This content is not written by or endorsed by "WOWK", its advertisers, or Nexstar Media Inc.

Ultima Genomics doubles read output in $60 genome push. Ultima Genomics pairs higher sequencing output with workflow upgrades, while its $60 genome claim leaves labs to assess total costs and usable data quality. Key facts. * Platform update: Paired-end sequencing is now available on the UG200 Series. * Maximum output: Solaris 2.0 Max workflows deliver up to 20 billion reads per wafer. * Capacity comparison: Solaris 2.0 Max doubles the output of existing Solaris 2.0. * Cost claim: Ultima says the launch enables a $60 genome; the supplied details do not define all included costs. Ultima Genomics launched paired-end sequencing and Solaris 2.0 Max at ASHG 2026, with workflows delivering up to 20 billion reads per wafer and enabling what the company calls a $60 genome. Ultima Genomics is pairing a substantial increase in sequencing output with a change in how its instruments read DNA, linking the launch to a claimed $60 genome. The practical question for laboratories is whether those advances translate into cheaper, usable genetic information after the rest of the workflow is included. At ASHG 2026, the company launched paired-end sequencing on its UG200 Series and introduced Solaris 2.0 Max workflows. The latter deliver up to 20 billion reads per wafer, double the output of existing Solaris 2.0, according to the company announcement carried by PR Newswire Biotech. These are related but distinct developments. More reads can improve the economics of running a sequencing instrument. Paired-end sequencing can make the resulting data more useful and better suited to established analysis workflows. Neither improvement, by itself, establishes the total cost of delivering a finished genome analysis. Higher output changes the laboratory cost equation. A sequencing read is a measurement of a stretch of genetic material. Producing more reads from a wafer increases the amount of raw data available from that unit of processing. For laboratories with enough samples ready to run, that can create an opportunity to spread operating costs across more work. Ultima's stated maximum of 20 billion reads per wafer is therefore an important capacity measure. It is not, however, a count of completed genomes. How much sequencing a sample needs depends on the application, the desired depth of measurement and how much of the resulting data passes quality requirements. The phrase "up to" also matters. It describes the upper end of the announced output rather than a guaranteed result for every laboratory run. Buyers evaluating the upgrade will need to distinguish its stated capacity from the usable output they can reproduce with their own samples and procedures. Higher capacity is most valuable when a laboratory can keep it occupied. A facility with a steady flow of samples may be able to use the additional output efficiently. A smaller operation may instead face a choice between waiting to assemble a fuller run and processing samples sooner. That trade-off can affect both economics and turnaround time. Paired-end sequencing addresses usefulness, not just volume. Paired-end sequencing reads genetic fragments from both ends. The relationship between those readings can help analysis software place a fragment within a reference genome and interpret regions that are harder to resolve from a single reading direction. Ultima says the offering advances workflow compatibility and quality for germline whole genome sequencing and other applications. Germline analysis examines inherited genetic variation, rather than focusing solely on changes acquired in a particular tissue. In that setting, laboratories need reliable results across the genome, not simply a large volume of raw measurements. The compatibility element is commercially relevant because sequencing instruments do not operate in isolation. Laboratories prepare samples before sequencing, then use software and quality checks to turn the output into information researchers or clinicians can assess. A change in data format or characteristics can require adjustments throughout that process. The compatibility element is commercially relevant because sequencing instruments do not operate in isolation. Support for paired-end sequencing may make the platform easier to evaluate against workflows already built around that approach. But the supplied launch details do not quantify the improvement in accuracy or specify performance across different kinds of genetic variation. Those remain important questions for laboratories considering adoption. The $60 genome is not a complete laboratory bill. The headline cost claim is likely to draw attention because it offers a simple way to describe a technically complex product. Its usefulness depends on what is included. The available launch information says the technology enables a $60 genome, but does not provide a detailed accounting of that figure. A laboratory's full cost can include sample preparation, sequencing materials, instrument ownership, staff time, data storage and analysis. Additional review may be necessary depending on the intended use. Without a defined cost boundary, the announced figure should not be read as a universal price for a completed clinical test or interpreted genome. That distinction does not erase the potential significance of cheaper sequencing. If the sequencing component becomes less expensive while quality is maintained, research budgets could support broader sampling or more extensive measurement. The benefit would depend on whether other parts of the process can accommodate the additional work. Nor does doubling read output automatically mean halving the cost of every finished result. Some expenses vary with sample volume, while others depend on staffing, equipment or analysis requirements. The announcement establishes a higher output claim, not a proportional reduction in all laboratory spending. Adoption will depend on evidence beyond peak capacity. For prospective users, the most useful next step is an application-specific comparison. A laboratory studying inherited variation will want to know whether the new workflow produces the data quality its work requires, how consistently it performs and whether existing analysis tools can handle the output without extensive modification. Operational evidence matters alongside scientific performance. Laboratories will need to assess preparation requirements, run reliability, the frequency of repeat work and the computing resources needed to process larger data volumes. Savings at the sequencing stage can be diluted if downstream work becomes slower or more expensive. The launch does not establish a field-wide cost ranking. Comparing Ultima with other sequencing options would require matched assumptions about sample quality, sequencing depth, usable data and included expenses. A headline genome price alone cannot supply that comparison. Ultima's announcement nevertheless gives laboratories a concrete proposition to test: higher wafer output alongside paired-end data on the UG200 Series. The potential advance lies in combining volume with workflow usefulness. Whether that combination delivers the advertised economics will depend on reproducible performance and a clear accounting of what the $60 genome actually covers. Frequently asked questions. What did Ultima Genomics launch at ASHG 2026? Ultima Genomics launched paired-end sequencing on its UG200 Series and Solaris 2.0 Max workflows. The company says Solaris 2.0 Max delivers up to 20 billion reads per wafer, doubling existing Solaris 2.0 output. It also says the launch enables a $60 genome, without detailing the full cost calculation in the supplied information. What does paired-end sequencing do? Paired-end sequencing reads genetic fragments from both ends, giving analysis software related measurements that can help locate and interpret the fragments. Ultima says its offering advances workflow compatibility and quality for germline whole genome sequencing and other applications. The supplied announcement does not quantify the quality improvement across specific types of genetic variation. Does the $60 genome mean a complete genetic test costs $60? The supplied information does not establish that. Ultima says the launch enables a $60 genome, but does not define all included expenses. A completed test can involve sample preparation, staff time, instrument costs, storage, analysis and review. Laboratories need a clear cost breakdown before treating the figure as an all-inclusive test price. Does doubling read output double the number of completed genomes? Not necessarily. Ultima's output claim measures reads per wafer, rather than completed genome analyses. The number of samples a laboratory can process depends on required sequencing depth, usable data quality and the application. Higher raw output can expand capacity, but the announcement does not establish a universal count of finished genomes. Which laboratories could benefit from the higher output? Laboratories with enough samples to use the additional capacity could potentially spread sequencing expenses across more work. The benefit depends on sample volume, quality requirements and downstream resources. Smaller laboratories may need to balance fuller instrument runs against waiting time, while all users must assess whether their analysis systems can accommodate the output. What evidence should buyers examine before adopting the workflows? Buyers should examine usable data output, performance for their intended applications, workflow compatibility and the full cost of producing an acceptable result. Run reliability, repeat work and computing requirements also matter. Ultima's announced capacity and cost claims provide starting points for evaluation, but do not replace testing under a laboratory's own operating conditions.